dc.creatorMascarenhas C.D.C.
dc.creatorFerreira Da Cunha A.
dc.creatorBrugnerotto A.F.
dc.creatorGambero S.
dc.creatorDe Almeida M.H.
dc.creatorCarazzolle M.F.
dc.creatorPagnano K.B.B.
dc.creatorTraina F.
dc.creatorCosta F.F.D.
dc.creatorDe Souza C.A.
dc.date2014
dc.date2015-06-25T17:50:54Z
dc.date2015-11-26T15:38:13Z
dc.date2015-06-25T17:50:54Z
dc.date2015-11-26T15:38:13Z
dc.date.accessioned2018-03-28T22:46:43Z
dc.date.available2018-03-28T22:46:43Z
dc.identifier
dc.identifierLeukemia And Lymphoma. Informa Healthcare, v. 55, n. 8, p. 1861 - 1869, 2014.
dc.identifier10428194
dc.identifier10.3109/10428194.2013.855311
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-84904900099&partnerID=40&md5=31a1a5441939a95c0e8f7c92d4d234a2
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/85933
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/85933
dc.identifier2-s2.0-84904900099
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1263851
dc.descriptionDifferential gene expression analysis by suppression subtractive hybridization with correlation to the metabolic pathways involved in chronic myeloid leukemia (CML) may provide a new insight into the pathogenesis of CML. Among the overexpressed genes found in CML at diagnosis are SEPT5, RUNX1, MIER1, KPNA6 and FLT3, while PAN3, TOB1 and ITCH were decreased when compared to healthy volunteers. Some genes were identified and involved in CML for the first time, including TOB1, which showed a low expression in patients with CML during tyrosine kinase inhibitor treatment with no complete cytogenetic response. In agreement, reduced expression of TOB1 was also observed in resistant patients with CML compared to responsive patients. This might be related to the deregulation of apoptosis and the signaling pathway leading to resistance. Most of the identified genes were related to the regulation of nuclear factor κB (NF-κB), AKT, interferon and interleukin-4 (IL-4) in healthy cells. The results of this study combined with literature data show specific gene pathways that might be explored as markers to assess the evolution and prognosis of CML as well as identify new therapeutic targets. © 2014 Informa UK, Ltd.
dc.description55
dc.description8
dc.description1861
dc.description1869
dc.descriptionLuatti, S., Additional chromosomal abnormalities in Philadelphia-positive clone: Adverse prognostic influence on frontline imatinib therapy: A GIMEMA Working Party on CML analysis (2012) Blood, 120, pp. 761-767
dc.descriptionDeininger, M.W., Goldman, J.M., Melo, J.V., The molecular biology of chronic myeloid leukemia (2000) Blood, 96, pp. 3343-3356
dc.descriptionBaran, Y., Saydam, G., Cumulative clinical experience from a decade of use: Imatinib as first-line treatment of chronic myeloid leukemia (2012) J Blood Med, 3, pp. 139-150
dc.descriptionMelo, J.V., Hughes, T.P., Apperley, J.F., Chronic myeloid leukemia (2003) Hematology Am Soc Hematol Educ Program, pp. 132-152
dc.descriptionMascarenhas, C.C., New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors (2009) Leuk Lymphoma, 50, pp. 1148-1154
dc.descriptionWong, S., Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations (2004) Proc Natl Acad Sci USA, 101, pp. 17456-17461
dc.descriptionInokuchi, K., Chronic myelogenous leukemia: From molecular biology to clinical aspects and novel targeted therapies (2006) J Nippon Med Sch, 73, pp. 178-192
dc.descriptionPark, S., Application of array comparative genomic hybridization in chronic myeloid leukemia (2013) Methods Mol Biol, 973, pp. 55-68
dc.descriptionRemsing Rix, L.L., Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells (2009) Leukemia, 23, pp. 477-485
dc.descriptionCanalli, A.A., Granulocytic adhesive interactions and their role in sickle cell vaso-occlusion (2005) Hematology, 10, pp. 419-425
dc.descriptionDiatchenko, L., Suppression subtractive hybridization: A method for generating diff erentially regulated or tissue-specific cDNA probes and libraries (1996) Proc Natl Acad Sci USA, 93, pp. 6025-6030
dc.descriptionDiatchenko, L., Suppression subtractive hybridization: A versatile method for identifying diff erentially expressed genes (1999) Methods Enzymol, 303, pp. 349-380
dc.descriptionHillmann, A., Dunne, E., Kenny, D., CDNA amplification by SMARTPCR and suppression subtractive hybridization (SSH)-PCR (2009) Methods Mol Biol, 496, pp. 223-243
dc.descriptionEwing, B., Base-calling of automated sequencer traces using phred I. Accuracy assessment (1998) Genome Res, 8, pp. 175-185
dc.descriptionGhosh, S., Global gene expression and Ingenuity biological functions analysis on PCBs 153 and 138 induced human PBMC in vitro reveals diff erential mode(s) of action in developing toxicities (2011) Environ Int, 37, pp. 838-857
dc.descriptionGilmore, T.D., The Rel/NF-kappaB signal transduction pathway: Introduction (1999) Oncogene, 18, pp. 6842-6844
dc.descriptionSamy, R.P., Identification of a novel Calotropis procera protein that can suppress tumor growth in breast cancer through the suppression of NF-kappaB pathway (2012) PLoS One, 7, pp. e48514
dc.descriptionAlbensi, B.C., Mattson, M.P., Evidence for the involvement of TNF and NF-kappaB in hippocampal synaptic plasticity (2000) Synapse, 35, pp. 151-159
dc.descriptionLi, F., Sethi, G., Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy (2010) Biochim Biophys Acta, 1805, pp. 167-180
dc.descriptionPezzolesi, M.G., Comparative genomic and functional analyses reveal a novel cis-acting PTEN regulatory element as a highly conserved functional E-box motif deleted in Cowden syndrome (2007) Hum Mol Genet, 16, pp. 1058-1071
dc.descriptionBidere, N., Casein kinase 1alpha governs antigen-receptorinduced NF-kappaB activation and human lymphoma cell survival (2009) Nature, 458, pp. 92-96
dc.descriptionCerveira, N., Bizarro, S., Teixeira, M.R., MLL-SEPTIN gene fusions in hematological malignancies (2011) Biol Chem, 392, pp. 713-724
dc.descriptionZhao, L.J., Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia (2012) Blood, 119, pp. 2873-2882
dc.descriptionIchikawa, M., AML-1 is required for megakaryocytic maturation and lymphocytic diff erentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis (2004) Nat Med, 10, pp. 299-304
dc.descriptionBlackmore, T.M., The transcriptional cofactor MIER1-beta negatively regulates histone acetyltransferase activity of the CREBbinding protein (2008) BMC Res Notes, 1, p. 68
dc.descriptionKohler, M., Evidence for distinct substrate specificities of importin alpha family members in nuclear protein import (1999) Mol Cell Biol, 19, pp. 7782-7791
dc.descriptionMurati, A., Myeloid malignancies: Mutations, models and management (2012) BMC Cancer, 12, p. 304
dc.descriptionDaver, N., FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia (2013) Am J Hematol, 88, pp. 56-59
dc.descriptionBai, Y., Itch E3 ligase-mediated regulation of TGF-beta signaling by modulating smad2 phosphorylation (2004) Mol Cell, 15, pp. 825-831
dc.descriptionTzachanis, D., Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells (2001) Nat Immunol, 2, pp. 1174-1182
dc.descriptionNaka, K., TGF-beta-FOXO signalling maintains leukaemiainitiating cells in chronic myeloid leukaemia (2010) Nature, 463, pp. 676-680
dc.descriptionEzzeddine, N., Human TOB, an antiproliferative transcription factor, is a poly(A)-binding protein-dependent positive regulator of cytoplasmic mRNA deadenylation (2007) Mol Cell Biol, 27, pp. 7791-7801
dc.descriptionKundu, J., Tob1 induces apoptosis and inhibits proliferation, migration and invasion of gastric cancer cells by activating Smad4 and inhibiting betacatenin signaling (2012) Int J Oncol, 41, pp. 839-848
dc.languageen
dc.publisherInforma Healthcare
dc.relationLeukemia and Lymphoma
dc.rightsfechado
dc.sourceScopus
dc.titleIdentification Of Target Genes Using Gene Expression Profile Of Granulocytes From Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución